| ²é¿´: 860 | »Ø¸´: 3 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷ÕßÖÚÉñÖ®Éñ½«ÔùËÍÄú 5 ¸ö½ð±Ò | ||
ÖÚÉñÖ®Éñͳæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÐÄѪ¹Ü¼²²¡»ù´¡Ñо¿
|
|
|
½ñÌì±à¼»Ø¸´ÎÒÒªÓÐÐ޸Ļò»Ø´ðÒâ¼û£¬ ÓÐÒÔϼ¸µãÒâ¼û£¬²»ÖªµÀ¸ÃÔõô»Ø¸´£¨Ò»¹²Á½¸öÉó¸åÈË£© 1.ÈçºÎÔÚʵÑéÖÐÈ·¶¨ÖÐÒ©µÄµÍÖи߼ÁÁ¿£¨Ã»Óв鵽Ïà¹Ø¼ÁÁ¿µÄÎÄÏ×£© 2.the authors need to perform WGA staining ,Masson staining , sirus red staining and immunohistochemical analysis with antibodies against special markers of imflammatory cells.ÕâÑù×ÓÊÇÈÃÎÒ²¹×öʵÑéÂð,ÕâЩȾɫ¶¼×ö»¹ÊÇÖ»×ö¼¸¸öȾɫ¡£ 3.why is the target cell of GXST? Is it possible to discuss the molecular mechanisms of GXST in its target cell?Õâ¸öÔõôºÏÀí½âÊÍ£¬»ò»Ø¸´ »¹ÓÐÒ»¸öÉó¸åÈË˵ÕâÊÇ Ò»¸öÔã¸âµÄÑо¿£¬ÄÇÎÒÔõô»Ø¸´Õâ¸öÉó¸åÈË£¬»¹ÊǸÃÔõô°ì ÕâÑùÄÇÎÒ±»½ÓÊܵÄÏ£Íû»¹´óÂ𣿠лл£¬Â·¹ýµÄÇë¸øÎÒºÏÀíµÄ¼¸Ìõ½¨Ò飬ÎÒ»¹ÊÇÔÚ¿ÆÑзÉϵÄÐÂÊÖ¡£Ð»Ð» |
» ²ÂÄãϲ»¶
ר˶ 351 086100 Ò²ÊÇ¿¼µÄ²Ä¿Æ»ù ±¾¿ÆÒ²ÊDzÄÁÏ
ÒѾÓÐ8È˻ظ´
334Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸°²»Õ´óѧ0817»¯Ñ§¹¤³ÌÓë¼¼Êõ£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ4È˻ظ´
085601£¬Ò»Ö¾Ô¸Ïôó334¸´ÊÔ±»Ë¢Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çó²ÄÁϵ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ289·Ö
ÒѾÓÐ10È˻ظ´
²ÄÁÏ¿¼Ñе÷¼Á
ÒѾÓÐ10È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ12È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ÖÚÉñÖ®Éñ
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 8
- Ìû×Ó: 25
- ÔÚÏß: 25.6Сʱ
- ³æºÅ: 5083498
- ×¢²á: 2016-10-03
- ÐÔ±ð: GG
- רҵ: ·¨Ò½Ñ§
2Â¥2020-04-20 11:16:08
Silenceuil
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 345.1
- É¢½ð: 38
- Ìû×Ó: 133
- ÔÚÏß: 25.4Сʱ
- ³æºÅ: 19963757
- ×¢²á: 2019-11-29
- רҵ: ΢ÉúÎïÉúÀíÓëÉúÎﻯѧ
3Â¥2020-04-21 01:50:52
ÉöСÇò
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 113.5
- Ìû×Ó: 17
- ÔÚÏß: 1.7Сʱ
- ³æºÅ: 21790496
- ×¢²á: 2020-04-11
- רҵ: Ò©Îï¡¢»ùÒòÔØÌåϵͳ
4Â¥2022-08-21 21:38:38














»Ø¸´´ËÂ¥